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Abstract
Exercise performance depends on both physiological abilities (e.g., muscle strength) and behavior-
al characteristics (e.g., motivation). We tested the hypothesis that evolution of increased aerobic
exercise performance can be facilitated by evolution of neuropsychological mechanisms respon-
sible for motivation to undertake physical activity. We used a unique model system: lines of bank
voles Myodes glareolus selected for high swim-induced aerobic metabolism (“aerobic” A lines).
In generation 21, voles from the 4 A lines achieved a 57% higher “voluntary maximum” swim-
induced aerobic metabolism (VO2swim) than voles from 4 unselected, “control” C lines. In C lines,
VO2swim was 9% lower than the maximum forced-exercise aerobic metabolism (VO2run;
P¼ 0.007), while in A lines it was even higher than VO2run, although not significantly (4%, P¼ 0.15).
Thus, we hypothesized that selection changed both the aerobic capacity and the neuronal mecha-
nisms behind motivation to undertake activity. We investigated the influence of reuptake inhibitors
of dopamine (DARI), serotonin (SSRI), and norepinephrine (NERI) on VO2swim. The drugs
decreased VO2swim both in C and A lines (% decrease compared with saline: DARI 8%, P< 0.001;
SSRI 6%, P<0.001; NERI 8%, P< 0.001), but the proportional response differed between selection
directions only for NERI (stronger effect in C lines: P¼0.008) and the difference was marginally
non-significant for SSRI (P¼ 0.07) and DARI (P¼0.06). Thus, the results suggest that all the 3 mono-
amines are involved in signaling pathways controlling the motivation to be active and that norepin-
ephrine could have played a role in the evolution of increased aerobic exercise performance in our
animal model.
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The actual level of physical activity of an organism depends on both
its physical and physiological abilities (e.g., muscle strength) and be-
havioral characteristics (e.g., motivation to perform exercise; Good
et al. 2015; Garland et al. 2011). Many studies highlight importance
of the latter in the physical activity of humans and other animals,
but the neurobiological basis of increased voluntary physical activity
is not fully recognized (see review: Garland et al. 2011; de Geus
et al. 2014; Rosenfeld 2017). Understanding the mechanisms is cru-
cial for preventing alarmingly growing prevalence of several
civilization diseases resulting from low levels of physical activity of
humans (Bauman et al. 2012). Neuronal factors underlying the mo-
tivation to involve into physical activity or to perform at the upper
level of physical abilities are also of interest in evolutionary science
(Lightfoot 2013). It has been proposed that evolution of perform-
ance traits is driven by natural selection operating primarily on be-
havior, but the range of behaviors is limited by animals’
performance, and therefore selection impels subsequent morpho-
physiological changes underlying the performance (Garland and
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Carter 1994). As survival and reproductive success depend on
behaviors that usually require increased physical activity (e.g., mat-
ing, foraging, avoiding predators; Ekkekakis et al. 2005), neurobio-
logical rewards (e.g., “the runners high” pleasurable feeling of
euphoria after running) could play a role in the evolution of
increased performance (Ekkekakis et al. 2005).
In this study, we tested the hypothesis that evolution of an
increased aerobic exercise performance can be facilitated by evolu-
tion of motivation to undertake physical activity. We use the term
“motivation” for all behavioral aspects regulating the level of phys-
ical activity, as opposed to physical “ability” (Garland et al. 2011;
Good et al. 2015; Brellenthin et al. 2017). We used a unique animal
model: bank voles from a selection experiment (Sadowska et al.
2008, 2015; Jaromin et al. 2016). After 19 generations of selection
for high swim-induced aerobic metabolism (VO2swim) voles from
the A-selected lines (“Aerobic”) achieved a 61% higher mass-
adjusted metabolism than those from unselected C lines (“Control”;
Jaromin et al. 2016; Supplementary Figure S1.1). This difference in
VO2swim remains significant through the whole life of the voles
(Rudolf et al. 2017). Voles from the A lines have also a higher basal
metabolic rate (Sadowska et al. 2015) and are more active in open-
field test than voles from the C lines (Maiti et al. 2018, accepted for
publication). A whole transcriptome analysis indicated several puta-
tive candidate genes with an altered expression level or single-nu-
cleotide polymorphisms (SNP) frequency, and revealed that the
selection differences were mostly due to the changes in expression
rather than changes in SNP frequencies (Konczal et al. 2016, 2015).
Noteworthy, the VO2swim may not be the maximum metabolism
per se (the aerobic capacity), because the voles can float on the water
surface, and therefore are not forced to use their maximal abilities.
Thus, VO2swim can be treated as a measure of the maximum volun-
tary intensity of the exercise. Not surprisingly, in generation 5,
VO2swim in both A and C lines was about 23% lower than the
maximum forced-running rate of aerobic metabolism (VO2run;
Supplementary Table S1.1). Presumably, the external motivation to
undertake vigorous activity applied during forced running trial (elec-
tric shocks) is higher than that during swimming (in warm water). In
generation 19, however, C-line voles still achieved 19% lower
VO2swim than VO2run, while A-line voles achieved similar VO2
during swimming and running (Jaromin et al. 2016). Thus, it seems
that both the physical abilities and behavior (motivation to exercise)
evolved in our model system. We hypothesize that in the A lines sig-
naling of neurotransmitters involved in high motivation increased,
or signaling associated with loss of motivation to exercise decreased.
Physical activity is regulated by a complex network, which
includes, among others, neuronal pathways associated with mono-
amine neurotransmitters. For instance, dopamine is implicated in
motivation, rewarding, and motor movement (Vallone et al. 2000;
Knab and Lightfoot 2010). Serotonin is involved in regulation of fa-
tigue and locomotion (Davis and Bailey 1997). Norepinephrine reg-
ulates the level of arousal, reward mechanisms, and consciousness
(Roelands and Meeusen 2010). According to the central fatigue hy-
pothesis, these monoamines, and especially changes in their concen-
tration ratios, influence the drive to be active and determine the
capacity to perform exercise (Roelands and Meeusen 2010).
To investigate differences between the A and C lines in the monoa-
minergic signaling pathways we used a pharmacological approach,
based on the assumption that a change in neurophysiological mechan-
ism underlying a behavioral trait alters a behavioral or physiological
response to pharmacological agents. This approach (i.e., manipulation
of a neurotransmission by systemic drug administration) is widely
applied to investigate the involvement of monoamines in exercise per-
formance of both animals and humans (review in Roelands and
Meeusen 2010). It is especially useful when a large number of animals
has to be tested (which may practically preclude applying more sophis-
ticated neurophysiological methods), as it is in the case of selective
breeding experiments. The approach has been already successfully
used within the framework of other selection experiments (e.g.,
Rhodes et al. 2001; Rhodes and Garland 2003; Keeney et al. 2008,
2012). For instance, administration of a dopamine reuptake inhibitor
(RI) (a drug that effectively increases the dopaminergic signaling)
resulted in decreased activity of mice selected for high wheel-running
behavior, but had little effect on unselected, control mice (Rhodes
et al. 2001). This differential response suggested differences in dopa-
mine signaling between high wheel-runners and control mice. Indeed,
the level of brain dopamine in high wheel-runners was decreased
(Waters et al. 2013). Similarly, hyperactivity of patients with dopa-
mine signaling impairment (Attention Deficit Hyperactivity Disease,
ADHD) is decreased after stimulants administration, while the drugs
usually increase the activity of a healthy person (Jafarinia et al. 2012).
Our previous work showed no effect of bupropion (a non-selective
dopamine and norepinephrine RI) on aerobic performance of bank
voles (Jaromin et al. 2016). In this study, instead of nonselective drugs
(such as amphetamine or cocaine), we used selective agents to investi-
gate potential changes in particular neurotransmission: selective RIs of
dopamine (DARI, vanoxerine), serotonin (SSRI, fluoxetine), and nor-
epinephrine (NERI, reboxetine). As these drugs exert mainly central
monoaminergic effects, a distinct reaction to drugs administration in
the A and C lines will indicate that a particular neurotransmitter sig-
naling pathway has been changed due to selection (Rhodes et al. 2001;
Rhodes and Garland 2003; Keeney et al. 2008, 2012).
Material and Methods
Animals
We used bank voles Myodes glareolus from the artificial selection
experiment, in which 4 replicate lines of voles are selected for the 1-
min maximum rate of oxygen consumption achieved during 18-min
swimming trial at 38C (VO2swim; “A”—aerobic lines) and 4 repli-
cate lines of unselected, randomly bred voles are maintained as con-
trol (“C”). The rationale of the entire experimental evolution
project and the choice of bank voles as the model organism, details
of the selection procedure, and animal maintenance are described in
Sadowska et al. (2008, 2015). In generation 21, we measured
VO2swim in 1032 A-line voles and 259 C-line voles at the age of
75–85 days as a part of the regular selection protocol (selection
trial). The A-line voles with the highest VO2swim were used for
reproduction and could not be included in the pharmacological
experiment. Thus, to avoid the bias, we excluded also A-line voles
that achieved the lowest VO2swim, and chose C-line voles from the
middle of the distribution, too. Voles that could not swim or were
diving were excluded. In that way, we chose 6 females and 6 males
from each of the A and C lines (a total of 96, each representing a
different family) for each of the 2 experiments (with DARI and with
SSRI/NERI). The voles were assigned to 3 blocks in each experiment
(2 voles from each replicate line and sex in 1 block, tested on the
same day).
Pharmacological experiments
At the age of 100–165 days the voles underwent a series of 3 post-
injection VO2swim measurements. We applied the specific RIs of
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dopamine (vanoxerine), noradrenaline (reboxetine), and serotonin
(fluoxetine) that, according to literature, influence physical activity
in many different rodent species, including bank voles (fluoxetine
only: Meers and O¨dberg 2005; Korff et al. 2008). These RIs were
also successfully used in similar studies concerning the comparison
between lines of rodents selected for locomotor performance traits
(Wong et al. 2000; Rhodes et al. 2001; Cryan et al. 2005a, 2005b;
Meers and O¨dberg 2005; Korff et al. 2008; Esumi et al. 2013). The
exact doses were chosen based on results of pilot trials.
Because of pioneering nature of our animal model, we preceded
the main experiment with pilot trials, in which we assessed the effect
of the drugs administration on spontaneous activity of voles in their
home cages. The aim of the pilot trials was to exclude the possibility
that the dosages of the drugs applied in other studies were too high
for bank voles (e.g., causing immediate sedation, which would pre-
clude swimming trials) or too low and not resulting in any detect-
able change of behavior. We used 4 females and 4 males from each
of the A and C lines in a repeated measures design. During subse-
quent trials, each individual was injected intraperitoneally with
either vanoxerine (DARI; 10 mg/kg or 20 mg/kg), reboxetine (NERI;
10 mg/kg or 20 mg/kg), fluoxetine (SSRI; 10 mg/kg or 20 mg/kg), or
saline (a control). Additionally, each individual was injected with
a less specific RI of dopamine and noradrenaline (bupropion;
20 mg/kg, 30 mg/kg) as a preparation for another experiment
(Jaromin et al. 2016). The injections were counterbalanced and
administered in random order. We maintained 3-day breaks be-
tween the trials to avoid a carry-over effect. A complete description
of the measurement protocol, statistical analyses, and results of the
pilot trials is presented in Supplementary Materials. Shortly, DARI
in the low dose increased and in high dose decreased the activity,
although the effect of the low dose was not significant (low dose:
P¼0.87, high dose: P¼0.007; Supplementary Figure S2.1 and
Table S2.3). We observed a significant decrease of activity after
injection of both doses of NERI (P<0.001) and the high dose of
SSRI (low dose: P¼0.94, high dose: P<0.001).
In the proper study, to minimize the number of trials repeated on
the same individual (and hence an effect of training), we performed
2 experiments on separate groups of animals: 1 with DARI treat-
ment and the other with NERI and SSRI treatment. In each of the
2 experiments 3 swimming trials on each individual were performed
(i.e., the repeated measures design was applied). As some dopamine
RIs can give a differential effect depending on the dose administered,
for example, they increase activity in low dose and decrease activity
in high dose (e.g., Niculescu et al. 2005), and we also observed such
a pattern in the pilot trials (although the effect of the low dose was
not significant), we used 2 doses of DARI in the first experiment.
However, to strengthen the possibly differential response to DARI,
we decreased the low dose (to 5 mg/kg from 10 mg/kg used in the
pilot) and increased the high dose (to 25 mg/kg from 20 mg/kg).
In the second experiment, we chose the high dose of SSRI, as this
dose significantly decreased activity in the pilot trials. However, as
both doses of NERI decreased the voles activity in the pilot trials to
a similar level (Supplementary Figure S2.1), we chose the lower dose
to avoid side-effects that are more likely to occur in the case of too
high a dose, that is, an overdose (e.g., Whiskey and Taylor 2013).
Thus, in the experiment with DARI, animals received injections of
either saline, or DARI in low (5 mg/kg) or high dose (25 mg/kg).
In the experiment with SSRI/NERI, animals received injections of
either saline, or SSRI 20 mg/kg or NERI 10 mg/kg. Each individual
received 1 injection in 1 of the 3 measurement days. The injections
were administered in a random order, but we balanced the number
of each kind of injection administered to voles from a particular line
in each trial. To avoid carry-over effects, we maintained a 1 week
break between the repeated trials. All injections were administered
intraperitoneally, in a volume of 10 mL/kg, 30 min before the
VO2swim measurement. Vanoxerine hydrochloride, fluoxetine
hydrochloride, and reboxetine mesylate (Cayman Europe, Tallinn,
Estonia) were diluted in 0.9% saline (vanoxerine and fluoxetine
required sonification for 45 min–2 h in 40C) and filtered with syr-
inge filters with micropores 0.2 mm (Rotilabo, CarlRoth). The solu-
tions were freshly prepared every day, ca. 2 h before the trials.
Measurement techniques
The rate of oxygen consumption (VO2) was measured with
open-flow respirometric systems. We used 2 similar systems for the
measurement of swim-induced VO2 (VO2swim). The respirometric
chambers (a 15 cm diameter 3-L jar) were partly filled with water
(38C). The air flow (2 L/min) was controlled with mass-flow con-
trollers (GFC17 or GFC171S, Aalborg, Orangeburg, NY, USA).
A sample of excurrent air was dried with ND2 gas sample drier
(Sable Systems, Las Vegas, NV, USA) and with chemical absorber
(magnesium perchlorate), and directed to FC10 or FC-10a oxygen
and CA-2A CO2 analyzers (Sable system, Las Vegas, NV, USA),
which recorded the gas concentrations at 1-s intervals. The rates of
oxygen consumption were calculated with appropriate respirometric
equations and corrected for “effective volume” to achieve
“instantaneous” rates (Lighton 2008).
Behavior of the voles during the swimming trials was recorded
by waterproof cameras placed at the bottom of the chambers.
Recordings were analyzed in JWatcher version 1.0 by an observer
unaware of the treatment and selection direction for each animal.
The voles were scored as inactive (“immobility time”: floating
motionless or doing only small movements to keep nose above the
water surface) or active as either “swimming” (swimming around
the chamber in horizontal position, with forepaws usually not mov-
ing), “climbing” (swimming in upright position, with forepaws
moving partly above the water surface), “diving” (apparently deter-
mined swimming under water), or “drowning” (apparently uncon-
trolled submergence). As the last 2 categories were rare, and because
“climbing” behavior is especially interesting in the context of such
tests (see the “Discussion” section), statistical data analyses were
performed only for “proportion of activity” (the total activity time
divided by total trial time) and for “proportion of climbing” (climb-
ing time divided by the total activity time).
About 2 weeks after the pharmacological trials, we measured the
1-min maximum forced-running rate of oxygen consumption
(VO2run) in a respirometric treadmill for rodents (BTU-100-10-M,
Bio-Sys-Tech, Bialystok, Poland). The animals were forced to run
with mild electric shocks (0.5 mA) generated by bars located behind
the moving belt. The fur of the animal’s abdomen and hind legs was
moistened with water with a drop of dog shampoo, to increase elec-
tric conductivity. Without that procedure the animals ignored the
electric shocks. The treadmill started to move at 5 m/min 1 min after
starting the trial and the speed was increased by 5 m/min every mi-
nute. The test lasted untill exhaustion, that is, untill the animal was
unable to keep pace with the moving belt (typically 5–15 min).
To decrease velocity at which the voles achieved the maximum
effort (typically 25–75 m/min), and hence make the procedure safer
to the animals, the treadmill was inclined by 10. We also placed
2 ping-pong balls at the end of the moving belt, which helped the
animals learn faster to avoid the bars. The measurements were
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preceded by 2 habituation trials to familiarize the animals with the
treadmill. The habituation trials were performed in the same condi-
tions as the proper measurements. The method of oxygen and CO2
recording and of calculating VO2run was the same as for VO2swim.
All procedures associated with the breeding, selection, and ex-
perimental procedures were approved by the Local Ethical
Committee in Krakow, Poland (No. 68/2012 and No. 61/2014).
Statistical analyses
To analyze the data we used nested analysis of covariance
(ANCOVA) mixed models implemented in SAS 9.3 (SAS Institute
Inc., Cary, NC, USA) Mixed procedure (with REML estimation
method and variance components constrained to non-negative; SAS
Institute Inc., 2011). As the whole analyses included several complex
models, we provide—in addition to the verbal description presented
below—a Supplementary Material with a commented SAS code
used for the analyses.
The models used for analyzing the selection-trial body mass and
VO2swim included the following main fixed factors: line Type
(selected, control), Sex, and line Type  Sex interaction. The models
included also random effects (replicate Line nested in line Type,
Sex  Line interaction), fixed covariates (Age, litter Size), and cofac-
tors (Number of the litter of a female). In addition, the model for
VO2swim included Body mass as a covariate and Respirometric sys-
tem number as a cofactor. In the analyses performed for all voles
from generation 21 we included also a random effect of Family
nested in Line (the effect was not included in models for the pharma-
cological trials described in the next paragraph, because each indi-
vidual represented a different family).
To analyze data from the 3 subsequent pharmacological trials
we used similar ANCOVAs, but in repeated-measures design.
The analyses were performed for the following dependent variables:
1-min maximum VO2swim, time of achieving the 1-min maximum
VO2swim, mean VO2swim (mean VO2swim calculated for the
whole trial), proportion of activity, proportion of “climbing,” and
proportional response (the ratio of VO2swim after drug to that after
saline). These models included the same between-subjects effects as
described above (plus measurement Block as an additional random
effect), and the following within-subject (within-individual) effects:
fixed factors of a Drug (DARI experiment: DARI low dose vs. DARI
high dose vs. saline; SSRI/NERI experiment: SSRI vs. NERI vs. sa-
line), line Type  Drug interaction and trial Number (a repeated
measure factor), and random effect of DrugLine interaction. The
proportion of activity was arcsine-transformed (arcsine of the square
root of a value). Based on Akaike Information Criteria (AIC), we
chose compound symmetry as the best-fitted covariance structure.
A repeated measures ANCOVA was also used to compare
VO2swim (after saline injection only) with VO2run. The model
included the same between-subjects effects as described above and
the following within-subject effects: fixed factors of Exercise type
(swim vs. run; a repeated measure factor) and Exercise type  line
Type interaction, and random effect of Line  Exercise type. We
performed this analysis on pooled data from both pharmacological
experiments, so we included Experiment type as an additional cofac-
tor and random effect of Family nested in Line.
All initial models included interactions between Sex and other
main factors. However, these effects were not of the main interest
and were excluded from the final models when not significant
(P>0.05). To test for the homogeneity of slopes we included inter-
actions between Body mass and main factors, which were excluded
from the final models when not significant. However, the slopes of
the relationships between oxygen consumption rate (VO2) and Body
mass were always steeper in A than in C lines, and that difference
was significant in some analyses. To investigate whether the levels
of VO2 differ between the line Types in the range of observed body
mass, we tested this effect also at specific values of the mass (option
“at” in LSMEANS statement in the SAS Mixed procedure; SAS
Institute Inc., 2011). For a more transparent presentation of the
results, the adjusted least-squares means (LSM) presented on figures
were calculated at mean values of covariates (body mass and age:
24.0 g and 84 days in selection trial; 24.6 g and 136 days in further
trials; litter size: 6).
In all models, we used the Satterthwaite’s approximation to
calculate the effective denominator degrees of freedom (dfs) of the
F-statistics (SAS Institute Inc., 2011). Shortly, in the model with
nested random effects, the appropriate denominator dfs are com-
puted as combination of the dfs of appropriate random effects (i.e.,
the nested factor effects and residual term) weighted by variance
contributed by the effects. When the variance of the nested factor
(in our case replicate Lines nested in line Type) approaches zero, the
appropriate denominator df approach dfs for the residual error term
(which reflects the fact that in the absence of the among-group vari-
ance, individual observations can be effectively treated as independ-
ent). Thus, when the Satterthwaite method is used, the denominator
dfs can take any value from the range between the df of the nested
random factor and the df of residual term.
Unless otherwise stated, we used Tukey–Kramer for multiple
pairwise comparisons between groups or Dunnett comparisons be-
tween saline-drug groups. In all the models variance was constrained
to positive values. We tested the significance of random factors with
likelihood ratio test. For that purpose we fitted models such as
described above, but with the variance constraint relaxed
(“noboud” option in the Proc Mixed statement in SAS; SAS Institute
Inc., 2011).
In the “Results” section, we report main effects of line Type and
Drug. For descriptive statistics and detailed information about all
others effects see Supplementary Tables S1.2–S1.7.
Results
Effects of selection
Body mass in the selection trial ranged from 13.4 g to 38 g (mean:
24 g; Figure 1A and Supplementary Table S1.2). Body mass did not
differ significantly between A and C lines (F1,6¼2.91, P¼0.14).
Males were heavier than females and line Type Sex interactions
were not significant (Supplementary Table S1.4).
Both the swim-induced (VO2swim) and run-induced (VO2run)
oxygen consumption increased with body mass (Figure 1 and
Supplementary Table S1.3). For VO2swim, the slope of the relation-
ship was higher in A than in C lines, and the mass-adjusted
VO2swim was significantly higher in A than in C lines at the min-
imum body mass (P<0.0001), which implies that it was also true in
the entire range of body mass. In A lines the levels of VO2swim and
VO2run were similar (t7¼2.47, P¼0.15), while in C lines
VO2swim was lower than VO2run (t7¼4.91, P¼0.007; overall
ANCOVA: Exercise type: F1,7¼2.84, P¼0.14, line TypeExercise
type: F1,7¼27.1, P¼0.001; Figures 1B and 2). Voles from the
selected lines had also higher values of mean VO2swim, proportion
of activity time, and proportion of “climbing” behavior during the
swimming trials (Figures 3 and 4, and Table 1; details of the results
are presented below).
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Figure 1. The relationship between swim-induced (VO2swim) or run-induced (VO2run) 1-min maximum rate of oxygen consumption and body mass in bank
voles, and the effects of selection, sex, and pharmacological manipulation on the level of VO2swim. (A) VO2swim in all individuals from generation 21 (C, Control
lines; A, Aerobic lines) tested as a part of the selection experiment (selection-trial results). (B) The effect of Exercise type (VO2swim vs. VO2run) in voles from C
(N¼96) and A (N¼96) lines (voles used in DARI and NERI/SSRI experiments combined). (C) The effect of DARI (vanoxerine) in low and high dose on VO2swim:
repeated trials in a subsample of voles from C (N¼48) and A (N¼48) lines. (D) The effect of SSRI (fluoxetine) and NERI (reboxetine) on VO2swim: repeated trials
in a subsample of voles from C (N¼ 48) and A (N¼48) lines. Dotted lines indicate the mean body mass for which the adjusted least-squares means were calcu-
lated (shown in Table 1 and Figures 2–4).
Figure 2. The swim-induced rate of oxygen consumption achieved during the selection trial and pharmacological trials (swim trials 1–3 after saline injections
only), and the maximum forced-exercise (running) rate of oxygen consumption in bank voles from selected, aerobic A lines (N¼ 96) and unselected, control
C lines (N¼96). The adjusted least squares means for the mean body mass (24 g) with 95% confidence limits (LSM [95% CL]; note: an overlap of the confidence
limits does not indicate a lack of difference between repeated measurements at different conditions, because the confidence limits are based on among-individ-
ual variation at particular conditions, whereas the inferences concerning differences between conditions are based on within-individual comparisons. See
Table 1 for results of the proper significance tests).
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DARI experiment
The 1-min maximum VO2swim increased through the 3 subsequent
trials (trial 1 vs. trial 2: t186¼2.93, P¼0.01, trial 2 vs. trial 3:
t184¼1.60, P¼0. 25, trial 1 vs. trial 3: t187¼4.46, P<0.001;
Supplementary Table S1.5). The VO2swim was higher in A than C
lines (P<0.0001; Figures 1C and 3A, and Table 1). Only the high
DARI dose decreased VO2swim (compared with saline: Low Dose:
t184¼0.54, P¼0.81, High Dose: t185¼7.09, P<0.0001, Figures 3A
and 5A), but the line TypeDose interaction was not significant
(P¼0.35). As DARI in the Low Dose had practically no effect, we
performed a separate analysis only for the high dose, but the line
TypeDose interaction remained not significant (F1,91¼1.47,
P¼0.23). The time of achieving VO2swim did not depend on line
Type, Dose, or line TypeDose interaction (P>0.24; Figures 3B
and 5B). As in the analysis of 1-min maximum VO2swim, whole-trial
mean VO2swim (typically about 16 min) was higher in A than in C
lines and decreased after the high dose, but line TypeDose inter-
action was not significant (Figures 3C and 5C, and Table 1).
The proportion of activity time decreased in the third trial when
compared with the first and second trail (trial 1 vs. trial 2:
t134¼0.09, P¼0.99, trial 2 vs. trial 3: t133¼3.55, P¼0.001, trial 1
vs. trial 3: t126¼3.67, P¼0.001; Supplementary Table S1.5). Voles
from A lines were more active than those from C lines (P¼0.02;
Figure 3D and Table 1) and had a higher proportion of “climbing”
(P¼0.008; Figure 3E). The drug did not influence significantly ei-
ther the overall activity or the proportion of “climbing” (P>0.18;
Figure 5D,E).
Note that in the additive models (results reported above) the
line TypeDose interactions conveys the information on the effect
of selection on monoamines pathway. However, in the analysis of
the proportional response to the drug (the ratio of VO2swim after
drug to that after saline) the effect of selection on monoamines
pathway is expressed directly in the line Type effect. The overall
line Type effect was not significant (P¼0.19; Figure 3F and
Supplementary Table S1.6), but the proportional response to the
High Dose was much stronger than to the Low Dose (P¼0.0009;
Figure 5F), and the line TypeDose interaction was nearly signifi-
cant (P¼0.06). An analysis performed separately for the 2 doses
showed that the proportional response to High Dose tended to be
stronger in C than in A lines (C vs. A comparisons with Sidak cor-
rection: Low Dose: F1,18¼0.01, P¼1, High Dose: F1,18¼5.43,
P¼0.06; Figure 5F).
Figure 3. Summary of the main results from experiment with DARI (vanoxerine) in low and high dose: repeated trials in a subsample of voles from selected A
(N¼48) and unselected C lines (N¼ 48). (A) The swim-induced 1-min maximum rate of oxygen consumption (VO2swim). (B) The time when voles achieved the
VO2swim. (C) Whole-trial mean VO2swim (typically about 15 min). (D) Duration of activity divided by whole trial duration (proportion of activity); back-trans-
formed least squared means. (E) Duration of climbing divided by duration of activity (proportion of “climbing”). (F) The ratio of VO2swim achieved after drug to
the one after saline (proportional response). Bars represent adjusted least squares mean with 95% confidence limits (LSM [95% CL]; note: as explained in Figure
2 legend, an overlap of the confidence limits does not indicate that a difference is not significant. See Figure 5 and Table 1 for results of the proper significance
tests).
414 Current Zoology, 2019, Vol. 65, No. 4
D
ow
nloaded from
 https://academ
ic.oup.com
/cz/article-abstract/65/4/409/5067979 by Jagiellonian U
niversity user on 06 Septem
ber 2019
SSRI/NERI experiment
The 1-min maximum VO2swim increased through the 3 subse-
quent trials (trial 1 vs. trial 2: t176¼3.97, P¼0.003, trial 2 vs. trial
3: t174¼0.75, P¼0.73, trial 1 vs. trial 3: t173¼3.28, P¼0.004;
Supplementary Table S1.7). The VO2swim was higher in A than C
lines (P<0.0001; Figures 1D and 4A, and Table 1). Both drugs
decreased VO2swim (compared with saline: SSRI: t12¼5.63,
P¼0.0001, NERI: t11¼7.36, P<0.0001; Figure 5A), but the line
TypeDrug interaction was not significant (P¼0.31). The time of
achieving VO2swim was not significantly affected by the line Type
(P¼0.95; Figure 4B), but there was a significant line TypeDrug
interaction (P¼0.026). Specifically, in C lines the time of achiev-
ing VO2swim tended to be shorter after NERI (within line compar-
isons of drug vs. saline, with Sidak correction; F1,185¼5.40,
P¼0.08) and was not affected by SSRI (F1,189¼1.96, P¼0.51),
whereas A lines tended to achieve VO2swim later after injections
of NERI (F1,190¼2.34, P¼0.42) and SSRI (F1,190¼4.45,
P¼0.14). As in the analysis of 1-min maximum VO2swim, whole-
trial mean VO2swim was higher in A than in C lines and decreased
after the drugs injections, but line TypeDrug interaction was not
significant (Figures 4C and 5C, and Table 1).
The proportion of activity time decreased in the third trial
when compared with the first and second trail (trial 1 vs. trial 2:
t186¼0.92, P¼0.63, trial 2 vs. trial 3: t187¼3.26, P¼0.004, trial
1 vs. trial 3: t187¼2.37, P¼0.05; Supplementary Table S1.7), and
tended to be higher in A than in C lines (P¼0.09; Figure 4D and
Table 1). The proportion was lower after SSRI than saline injection
(t188¼4.05, P<0.0001; Figure 5D), but it was not affected by
NERI (t188¼0.23, P¼0.96) or line TypeDrug interaction
(P¼0.13). The proportion of “climbing” increased through subse-
quent trials (trial 1 vs. trial 2: t175¼2.61, P¼0.03, trial 2 vs.
trial3: t175¼1.48, P¼0.30, trial 1 vs. trial 3: t175¼4.09,
P¼0.0002; Supplementary Table S1.7) and was higher in A than
in C lines (P¼0.0002; Figure 4E and Table 1), but was not affected
by the drugs (Drug: P¼0.32, line TypeDrug: P¼0.51;
Figure 5E).
The proportional response to drugs (the ratio of VO2swim after
drug to that after saline) was stronger in C than in A lines (line
Type: P¼0.004; Figure 5F), but the difference for SSRI was margin-
ally non-significant (C vs. A comparisons with Sidak correction:
NERI: F1,129¼9.07, P¼0.008, SSRI: F1,132¼4.89, P¼0.07;
Figure 4F and Supplementary Table S1.6). The Drug effect was
Figure 4. Summary of the main results from experiment with SSRI (fluoxetine) and NERI (reboxetine): repeated trials in a subsample of voles from selected A
(N¼48) and unselected C lines (N¼ 48). (A) The swim-induced 1-min maximum rate of oxygen consumption (VO2swim). (B) The time when voles achieved the
VO2swim. (C) Whole-trial mean VO2swim (typically about 15 min). (D) Duration of activity divided by whole trial duration (proportion of activity); back-trans-
formed least squared means. (E) Duration of climbing divided by duration of activity (proportion of “climbing”). (F) The ratio of VO2swim achieved after drug to
the one after saline (proportional response). Bars represent adjusted least squares mean with 95% confidence limits (LSM [95% CL]; note: as explained in Figure
2 legend, an overlap of the confidence limits does not indicate that a difference is not significant. See Figure 5 and Table 1 for results of the proper significance
tests).
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Table 1. Main results of mixed ANCOVA models (effects of selection, pharmacological treatment, and their interaction) for the data obtained
in DARI and SSRI/NERI experiments
Experiment Line Type Dose/Drug Line TypeDrug
Trait t (df), P-value F (Ndf, Ddf), P-value F (Ndf, Ddf), P-value
DARI experiment
VO2swim 10.0 (7), <0.0001 31.6 (2, 185), <0.0001 1.03 (2, 185), 0.36
Time of achieving VO2swim 0.95 (12), 0.36 1.60 (2, 14), 0.24 1.59 (2, 14), 0.24
Mean VO2swim 7.93 (7), 0.0001 22.8 (2, 11), 0.0001 0.6 (2, 11), 0.58
Proportion of activity 3.22 (6), 0.02 0.1 (2, 91), 0.89 1.72 (2, 91), 0.18
Proportion of “climbing” 3.71 (7), 0.008 0.3 (2, 176), 0.70 1.00 (2, 176), 0.38
Proportional response 1.35 (29), 0.19 30.6 (1, 7), 0.0009 4.87 (1, 7), 0.06
SSRI/NERI experiment
VO2swim 12.2 (7), <0.0001 29.6 (2, 11), <0.0001 1.31 (2, 11), 0.31
Time of achieving VO2swim 0.06 (7), 0.95 2.01 (2, 188), 0.14 3.73 (2, 188), 0.03
Mean VO2swim 8.48 (6), 0.0001 48.6 (2, 11), <0.0001 1.50 (2, 11), 0.26
Proportion of activity 1.95 (6), 0.10 10.5 (2, 188), <0.0001 2.03 (2, 188), 0.13
Proportion of “climbing” 6.52 (8), 0.0002 1.26 (2, 11), 0.32 0.7 (2, 11), 0.51
Proportional response 2.99 (81), 0.004 3.29 (1, 85), 0.07 0.6 (1, 85), 0.43
Notes: VO2swim, 1-min maximum swim-induced rate of oxygen consumption; mean VO2swim, whole-trial mean VO2swim; proportional response, the ratio of
VO2swim achieved after drug to the one after saline; note that in the proportional response analysis the line TypeDrug interaction has only one degree of free-
dom and has different meaning than in the other analyses (see the sections “Materials and Methods” and “Discussion” for details); F- or t-statistics; df, degrees of
freedom; ndf, numerator df; ddf, denominator df; see Supplementary Tables S1.5 and S1.7 for results concerning additional factors in the ANCOVA models.
Figure 5. The effect of DARI (vanoxerine in low and high dose), SSRI (fluoxetine), and NERI (reboxetine) on the measured traits. (A–E) Mean within-individual dif-
ferences between the values obtained after drug treatment and saline injection (A, the swim-induced 1-min maximum rate of oxygen consumption [VO2swim];
B, the time when voles achieved the VO2swim; C, whole-trial mean VO2swim; D, duration of activity divided by whole trial duration; E, Duration of “climbing” div-
ided by duration of activity). (F) Difference between the A and C lines in the ratio of VO2swim achieved after drug to that after saline (proportional response). Bars
represent the least squares estimates of the mean differences with 95% confidence limits.
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marginally non-significant (P¼0.07) and line TypeDrug inter-
action was not significant (P¼0.43).
Discussion
As expected, in generation 21 of the selection experiment bank
voles from the A-selected lines achieved more than 57% higher
swim-induced aerobic metabolism (VO2swim) than those from the
unselected C-control lines (Figure 1A). As in our previous work, per-
formed on generation 19 (Jaromin et al. 2016), VO2swim was 9%
lower than the maximum forced-running aerobic metabolism
(VO2run) in C lines, but in the A lines the levels of VO2swim and
VO2run were practically the same (Figures 1B and 2). Thus, A-line
voles evolved both an increased aerobic capacity and an increased
motivation to be physically active. Observations of behavior showed
that during the swimming trials A-line voles spent more time on ac-
tive behavior, especially more time on “climbing,” than C-line voles
(Figures 3D,E and 4D,E). Such a profile is characteristic for animal
models of reduced depressive phenotypes, such as dopamine or nor-
adrenaline transporter knock-outs (Perona et al. 2008). To investi-
gate the effect of selection on the monoamine signaling pathways we
performed a series of pharmacological tests.
Although in a previous study we did not observe differences in
VO2swim across subsequent trials (Jaromin et al. 2016), here
VO2swim increased in the second trial of both of the pharmaco-
logical experiments, while activity time did not change
(Supplementary Tables S1.5 and S1.7). In the third trial, VO2swim
was still higher than in the first trial, while activity time decreased.
Those interesting results suggest that swimming in 38C, that is, at
temperature similar to the body temperature of voles, does not in-
duce an immediate despair syndrome (a decrease of active behavior)
in most individuals. The despair syndrome is connected with
repeated stressful situation and is observed in rodents subjected to
repeated forced swimming test (FST—about 5 min-long test per-
formed in 23–25C and widely used to investigate antidepressant
drugs characteristics; Dal-Zotto et al. 2000; Cryan et al. 2005a). As
ambient temperature is known to influence performance and the re-
sponse to drugs (Roelands and Meeusen 2010), the results of our
swimming trials and FSTs may not be directly compared.
All the drugs decreased VO2swim (note that the order of treat-
ments was randomized, so the reported effect of drugs is not due to
the measurement order). However, in the case of vanoxerine (DARI)
the result was opposite to that expected from studies on laboratory
rodents. As vanoxerine rapidly increases the level of dopamine 30 min
after injection, it usually increases physical activity in rats (e.g., Esumi
et al. 2013). However, it did not affect behavior in some swimming
tests with mice (Perona et al. 2008) or physical activity in humans (re-
view in Roelands and Meeusen 2010). In high doses, vanoxerine can
even decrease cardiac output (Knuepfer and Gan 1997), which is a
trait closely related to VO2. As bank voles are not used in standard
pharmacological experiments, the data concerning their response to
particular pharmaceuticals are scarce or lacking. As the response to
drugs differs greatly between species and even strains (Cryan et al.
2005b; Petit-Demouliere et al. 2005), the sometimes unexpected
results of the pharmacological trials can be specific for bank voles.
Fluoxetine (SSRI) decreased both VO2swim and the proportion of
activity time in the voles (Figures 4A,C,D and 5A,C,D). An opposite
response to that drug could have been expected as SSRIs usually de-
crease or do not change immobility time in FSTs (see review Cryan
et al. 2005a). However, as mentioned before, our swimming trials
should not be directly compared with FSTs. Our results are consistent
with the Central Fatigue Hypothesis, according to which the
increased concentration of extracellular serotonin in several brain
regions contributes to the induction of fatigue during prolonged exer-
cise (Meeusen et al. 2006; note that the fatigue occurring as a conse-
quence of physical exercise, that is, a physiologically “normal”
situation, is a state principally different from pathological fatigue
accompanying, for example, depression or chronic fatigue syndrome;
although SSRI can accelerate the onset of fatigue during exercise, they
can have a different effect in case of the pathological fatigue and are
used in the treatment of that disease; Thomas and Smith 2006).
Results from studies on animals suggest that pharmacological en-
hancement of serotoninergic signaling decreases physical perform-
ance. For instance, the injection of serotonin receptor agonist
decreases the running time to exhaustion in rats (review in Roelands
and Meeusen 2010) and SSRI decreases wheel running in mice
(Rhodes et al. 2001; Weber et al. 2009). However, pharmacological
manipulations of serotoninergic signaling in humans often do not in-
fluence the prolonged exercise (review in Meeusen and Roelands
2010). Thus, it was suggested that serotonin alone rather do not in-
duce fatigue during prolonged exercise, but may play some role in
combination with other neurotransmitter signaling (Meeusen and
Roelands 2010). Similarly, the response to reboxetine (NERI) in voles
was consistent with that reported in other studies concerning pro-
longed exercise, which generally show that selective NERIs decrease
physical performance (e.g., Roelands et al. 2008; Weber et al. 2009;
Klass et al. 2012; however, NERIs decrease immobility time during
FSTs; Wong et al. 2000). That paradoxical effect (reboxetine
increases the level of norepinephrine in a synaptic gap and norepin-
ephrine is widely recognized as an activator) could be due to an acti-
vation of inhibitory a2-autoreceptors that leads to a decrease in
norepinephrinergic neurons firing (Mitchell et al. 2006). In voles,
reboxetine decreased VO2swim (Figure 4A), but did not change the
proportion of activity time (Figure 4D). Apparently, VO2swim is a
more sensitive measurement of the exercise intensity than the simple
behavioral observation. The results cannot be used to make inferences
concerning the relative contributions of each monoaminergic system
to the motivation, as the specific drugs may inhibit the reuptake trans-
porters with different intensity (and moreover their dosages were ar-
bitrary). After the drugs administration, we did not observe any
suspicious symptoms, such as lack of a normal response to a stimuli
(e.g., the attempt to catch), bristled fur, uncoordinated movements,
trembling, etc. Thus, the observed decreased level of VO2swim should
be primarily due to modification of a particular monoamine signaling
pathway rather than occurrence of an adverse event (e.g., anxiety that
would decrease swimming and therefore the level of VO2swim). As
all the drugs influenced the intensity of “voluntary” exercise meas-
ured as the level of VO2swim, the results confirm involvement of the
monoamines in the motivation to be physically active. However, as
no compounds are completely specific (i.e., the “specific” drugs still
have some affinity to other neurotransmitter reuptake transporters
and receptors), it is possible that the drugs decreased VO2swim by
modifying also other signaling pathways. Because monoamines regu-
late many behavioral states, we cannot exclude a possibility that the
decreased VO2swim was an effect of, for example, decreased arousal
rather than decreased motivation. Thus, further studies are required
to confirm that the monoamines affect the voles’ activity by modify-
ing the “motivation” per se.
To investigate the effect of selection on monoamine signaling
pathways, we tested line Type  Drug interactions in additive mod-
els and line Type effect in the proportional response analyses. The
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interactions in additive models were not significant, except for the
analysis of the time of achieving VO2swim. Specifically, in C lines
the time of achieving VO2swim tended to be accelerated after NERI,
while in A lines it tended to be delayed after SSRI and NERI injec-
tions (Figure 4B). However, post hoc saline versus drug comparisons
performed for A and C lines separately were not significant.
Nevertheless, that differential response may indicate differences in
serotonin and norepinephrine signaling between A and C lines. The
proportional response to DARI in high dose, NERI, and SSRI was
stronger in C lines than in A lines, but the difference was significant
only in the case of NERI (Figures 4F and 5F). The result suggests
that norepinephrine signaling pathway is involved in the mechanism
responsible for differences in behavior between A and C lines, but
further studies are required to confirm the role of norepinephrine in
the evolution of increased aerobic exercise performance. In another
selection experiment with mice, administration of SSRI decreased
wheel running both in mice selected for high wheel running and
unselected, control mice (Rhodes et al. 2001). However, HPLC ana-
lysis of brain tissue indicated lower serotonin level in selected mice
when compared with unselected ones (Waters et al. 2013). The
selected mice respond differently to serotonin 5-HT1A receptor
agonist and antagonist than control mice (Claghorn et al. 2016).
Thus, possibly, usage of different methods (e.g., HPLC) or drugs in
future studies will allow better detection of potential differences in
monoamines concentration or signaling pathway in the brains of
voles from A and C lines.
It could be argued that the lack of clear differences between the
selected and control lines in response to the drugs resulted from the
fact that the effects of the drugs were generally small, and that the
effects could be stronger if higher doses were applied. However, in
the case of too high a dose (i.e., overdose) the peripheral side-effects,
for example, tachycardia, are more likely to occur (e.g., Borys et al.
1992; Whiskey and Taylor 2013), whereas the objective of this work
was to investigate the central monoaminergic effects of the drugs.
Moreover, a relevant pharmacological manipulation applied to test
hypotheses concerning mechanisms underlying evolution should not
lead to effects grossly exceeding the normal range of behavioral plasti-
city. Note also that we compensated for the (expected) small effect
size by performing the tests on a large number of animals.
The knowledge concerning neurobiological basis of behavior is
severely biased by results from experiments conducted on a few
model species (Keifer and Summers 2016). Our results suggest the
involvement of dopamine, serotonin, and norepinephrine in the
regulation of motivation to be physically active in a non-model spe-
cies of rodent. Moreover, the result suggests that evolution of
increased physical performance in bank voles can be associated with
changes in norepinephrine signaling. However, as the pharmaco-
logical approach has several limitations (e.g., not complete specifi-
city of the drugs and their systemic application), the conclusions
require an additional support. As the selection experiment is contin-
ued, further studies, for example, analyses of monoamine content in
brain tissue or molecular analyses of the expression and allelic dif-
ferences in genes coding monoamine receptors or involved in mono-
amine regulation (cf. Konczal et al. 2015, 2016), can be undertaken
to resolve the question about the role of these monoamines in the
evolution of increased aerobic exercise performance.
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